COSCIENS Biopharma's Management Cease Trade Order Explained

Author: Logan Wright Updated: 04-01-2025 07:30 PM

COSCIENS Biopharma's Announcement of Management Cease Trade Order

COSCIENS Biopharma Inc. (NASDAQ: CSCI) has made a significant announcement regarding the receipt of a management cease trade order (MCTO). This comes as the company acknowledges a potential delay in filing critical financial documents.

Understanding the Management Cease Trade Order

The Ontario Securities Commission (OSC) has accepted COSCIENS' application for the MCTO, which became effective as of April 1, 2025. The order is primarily linked to the delays in filing the annual financial statements for the years ending December 31, 2024, 2023, and 2022, along with other related documents.

Why the Delay?

COSCIENS has confirmed the inability to meet the March 31, 2025, deadline due to several factors, which were previously outlined in a Default Announcement. The company is currently working closely with its auditors to finalize the required filings and anticipates that these will be available shortly, no later than April 7, 2025.

Company Updates and Future Expectations

While the MCTO restricts trading of securities by certain company executives, it will not affect the trading activities of ordinary shareholders. Until the required documents are filed, COSCIENS has pledged to comply with the alternative information guidelines set by the OSC, which includes regular updates via news releases.

Impact on Nasdaq Listing

Importantly, the current situation with the MCTO will not have an immediate impact on COSCIENS’ common shares listed on the Nasdaq Capital Market. The company plans to submit the necessary Form 20-F promptly, though it cannot guarantee a specific filing date.

About COSCIENS Biopharma Inc.

COSCIENS is a renowned life science company resulting from the merger of Aeterna Zentaris and Ceapro Inc. The firm focuses on developing a diverse array of cosmeceutical, nutraceutical, and pharmaceutical products, particularly leveraging proprietary extraction technologies from renewable plant resources. Notable ingredients include oat beta glucan and avenanthramides, which are integral to leading skincare brands.

Continuous Commitment

The leadership at COSCIENS remains dedicated to ensuring clarity and prompt communication with stakeholders regarding its developments, especially concerning its financial filings and compliance with regulatory standards.

Investor Relations and Contact Information

For any questions or concerns, Gilles R. Gagnon, the President & CEO, is available for contact at +1 (780) 421-4555 or via email at ggagnon@cosciensbio.com. Additionally, investors can reach out to Jenene Thomas of the JTC Team at +1 (908) 824-0775 or through csci@jtcir.com.

Frequently Asked Questions

What is the Management Cease Trade Order (MCTO)?

The MCTO is an order issued by the OSC that restricts certain executives from trading the company’s securities until the required filings are submitted.

What caused the delay in financial filings?

COSCIENS has not specified the exact reasons for the delay but has indicated that they are working with auditors to finalize the documents.

How will this affect shareholders?

While executives are restricted from trading, regular shareholders can continue to trade their securities without any restrictions.

When does COSCIENS expect to file the required documents?

The company aims to file the necessary documents by April 7, 2025, at the latest.

What should investors do during this period?

Investors should stay informed through COSCIENS’ regular updates and reports to ensure they are aware of any developments.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.